CBU
LGND icon

CIBC Bancorp USA’s Ligand Pharmaceuticals LGND Stock Holding History

CIBC Bancorp USA’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$636K Buy
2,011
+878
+77% +$207K ﹤0.01% 1224
2026
Q1 		$226K Buy
+1,133
New +$224K ﹤0.01% 1553
2025
Q3 		$360K Buy
+2,034
New +$302K ﹤0.01% 1006

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Bancorp USA's LGND Position: Q2 2026 in Review

CIBC Bancorp USA increased its Ligand Pharmaceuticals (LGND) stake by 77% in Q2 2026, buying an estimated $207K and bringing the position to 2,011 shares worth $636K. The position accounts for ﹤0.01% of the portfolio, ranked #1224.

CIBC Bancorp USA first reported a position in LGND in Q3 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • CIBC Bancorp USA held 2,011 shares of Ligand Pharmaceuticals worth $636K as of Q2 2026.
  • CIBC Bancorp USA bought 878 Ligand Pharmaceuticals shares in Q2 2026, an estimated $207K.
  • Ligand Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1224 holding.
  • CIBC Bancorp USA first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.